Nerida Bell1, Claire L Hutchinson2, Timothy C Green1,3, Eileen Rogan2, Kendall J Bein1, Michael M Dinh1,3. 1. Emergency Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 2. Emergency Department, Canterbury Hospital, Sydney, New South Wales, Australia. 3. Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Abstract
OBJECTIVES: The aim of the study was to determine if oxygen delivered through humidified high flow nasal cannulae (HHFNC) reduced the need for escalation in ventilation management and work of breathing in the ED patients presenting with acute undifferentiated shortness of breath compared withstandard oxygen therapy. METHODS: This was an unblinded randomised control trial conducted at two hospital EDs in Sydney, Australia. Eligible patients presenting with shortness of breath were randomised to HHFNC or standard oxygen therapy. Primary outcomes were the need to escalate ventilation therapy or a reduction in respiratory rate of 20% or more within 2 h of commencement. RESULTS:One hundred patients were enrolled in the trial. The intervention group receiving HHFNC was associated with a higher proportion of patients with a reduced respiratory rate at 2 h (66.7% vs 38.5%, P = 0.005) and a lower proportion of patients requiring escalation in ventilation therapy (4.2% vs 19%, P = 0.02) compared with standard oxygen therapy. CONCLUSIONS: The use of high flow nasal cannula oxygenation was associated with improved respiratory state in selected patients presenting to the ED with acute undifferentiated shortness of breath.
RCT Entities:
OBJECTIVES: The aim of the study was to determine if oxygen delivered through humidified high flow nasal cannulae (HHFNC) reduced the need for escalation in ventilation management and work of breathing in the ED patients presenting with acute undifferentiated shortness of breath compared with standard oxygen therapy. METHODS: This was an unblinded randomised control trial conducted at two hospital EDs in Sydney, Australia. Eligible patients presenting with shortness of breath were randomised to HHFNC or standard oxygen therapy. Primary outcomes were the need to escalate ventilation therapy or a reduction in respiratory rate of 20% or more within 2 h of commencement. RESULTS: One hundred patients were enrolled in the trial. The intervention group receiving HHFNC was associated with a higher proportion of patients with a reduced respiratory rate at 2 h (66.7% vs 38.5%, P = 0.005) and a lower proportion of patients requiring escalation in ventilation therapy (4.2% vs 19%, P = 0.02) compared with standard oxygen therapy. CONCLUSIONS: The use of high flow nasal cannula oxygenation was associated with improved respiratory state in selected patients presenting to the ED with acute undifferentiated shortness of breath.
Authors: B Rochwerg; D Granton; D X Wang; Y Helviz; S Einav; J P Frat; A Mekontso-Dessap; A Schreiber; E Azoulay; A Mercat; A Demoule; V Lemiale; A Pesenti; E D Riviello; T Mauri; J Mancebo; L Brochard; K Burns Journal: Intensive Care Med Date: 2019-03-19 Impact factor: 17.440
Authors: Bruno L Ferreyro; Federico Angriman; Laveena Munshi; Lorenzo Del Sorbo; Niall D Ferguson; Bram Rochwerg; Michelle J Ryu; Refik Saskin; Hannah Wunsch; Bruno R da Costa; Damon C Scales Journal: JAMA Date: 2020-07-07 Impact factor: 56.272
Authors: Arianne K Baldomero; Anne C Melzer; Nancy Greer; Brittany N Majeski; Roderick MacDonald; Eric J Linskens; Timothy J Wilt Journal: Ann Intern Med Date: 2021-04-27 Impact factor: 25.391
Authors: Marina E Boules; Nabila Ibrahim Laz; Ahmed A Elberry; Raghda R S Hussein; Mohamed E A Abdelrahim Journal: Beni Suef Univ J Basic Appl Sci Date: 2022-04-15
Authors: Domenico Luca Grieco; Salvatore Maurizio Maggiore; Oriol Roca; Elena Spinelli; Bhakti K Patel; Arnaud W Thille; Carmen Sílvia V Barbas; Marina Garcia de Acilu; Salvatore Lucio Cutuli; Filippo Bongiovanni; Marcelo Amato; Jean-Pierre Frat; Tommaso Mauri; John P Kress; Jordi Mancebo; Massimo Antonelli Journal: Intensive Care Med Date: 2021-07-07 Impact factor: 17.440